MedChemComm

RESEARCH ARTICLE

Design and synthesis of fused soluble epoxide hydrolase/peroxisome proliferator-activated receptor modulators†

R. Blöcher, C. Lamers, S. K. Wittmann, O. Diehl, T. Hanke, D. Merk, D. Steinhilber, M. Schubert-Zsilavecz, A. S. Kahnt and E. Proschak*

Metabolic syndrome (MetS) is a widespread, complex disease cluster which consists of hypertension, atherosclerosis, dyslipidaemia and type II diabetes. The treatment of MetS requires multiple pharmaceutical agents leading to complex polypharmacy. Multi-target compounds might reduce the number of required drugs in MetS patients. In this study we fused three different pharmacophores of soluble epoxide hydrolase (sEH) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists. The most promising fused scaffold exhibits multi-target activity and represents a valuable starting point for design and evaluation of fused sEH/PPAR modulators.

Introduction

Metabolic syndrome (MetS) is a complex disease cluster with high prevalence in the western society.† Central obesity is regarded as the most relevant risk factor which is accompanied by dyslipidaemia, type II diabetes, and hypertension.‡ This so-called “deadly quartet” is accompanied by diverse complications leading to treatment with multiple pharmacological agents.§ Complex treatment regimen, also referred as polypharmacy, cause adverse effects, drug–drug interactions, and ultimately, failure of the therapy.¶ In this context, multi-target approaches offer a promising strategy to deliver safe and efficient drugs for the treatment of complex disease clusters.‖ Simultaneous modulation of soluble epoxide hydrolase (sEH) and peroxisome proliferator-activated receptor γ (PPARγ) was shown to exhibit synergistic effects in spontaneously hypertensive obese (SHROB) rats.¶ In this setting, a combination of the sEH inhibitor tAUCB and the PPARγ agonist rosiglitazone efficiently restored insulin sensitivity, lowered blood pressure, and protected the animals from nephropathy. Hypothetically, beneficial effects of dual sEH/PPARγ modulation might be enhanced by effective control of plasma lipids, which can be achieved by activation of PPARα.¶ Therefore, a simultaneous modulation of sEH, PPARγ, and PPARα might be a valuable profile of a multi-target agent for effective and safe MetS therapy.

PPARs are ligand-activated transcription factors which are involved in glucose and lipid homeostasis. PPARγ is targeted by thiazolidinediones (TZDs), also known as insulin sensitizers. Fibrates, which are clinically used for treatment of dyslipidemia are addressing all PPAR subtypes with slight preference for PPARα.¶ The role of sEH in cardiovascular disease associated with MetS is well known and has been excessively reviewed.¶ sEH converts epoxyeicosatrienoic acids (EETs) to the corresponding dihydroxyeicosatrienoic acids (DHETs) and sEH inhibition increases levels of EETs while decreasing levels of DHETs. The resulting increase in the EET/DHET ratio has multiple beneficial effects on the cardiovascular system. EETs are described as agonists of PPARγ and PPARα which subsequently promotes the expression of sEH.¶ Thus, there is a substantial crosstalk between sEH and PPAR activity supporting the assumption of synergistic targeting of the sEH/PPAR axis.¶ We have previously reported that it is possible to combine the pharmacophores of an sEH inhibitor and PPAR agonist using a combinatorial approach.¶ In the present study we have explored three different scaffolds on their potential for dual sEH/PPAR modulation.

Results and discussion

Our first attempt to obtain dual sEH/PPAR modulators was the incorporation of the simplified sEH pharmacophore 3-cyclohexyl-N'-iodophenylurea (CIU) into bezafibrate (Fig. 1). Bezafibrate is a pan-PPAR agonist exhibiting EC50 values in the micromolar range.¶ We decided to remove one of the methyl groups in α-position of the carboxylic acid and replaced the amide moiety by a urea residue. The resulting starting point 3c of our SAR study comprises a linker length similar to bezafibrate while 3d has an additional methylene unit in the linker region.

† The authors declare no competing interests.
The synthesis of compounds 3a–d was accomplished as shown in Scheme 1. Initially, ethyl 2-bromopropanoate was coupled with the corresponding phenol under Williamson conditions. Then, the nitrile residue was reduced with palladium on carbon as catalyst. The resulting primary amines 2a and 2b were coupled to 4-chlorophenyl isocyanate to yield ureas 3a and 3b.

Compounds 3a–d were evaluated in a fluorescence-based assay with recombinant sEH and all are able to inhibit sEH activity with submicromolar potency. Esters 3a and 3b were almost one order of magnitude more potent than the corresponding acids due to the hydrophobic nature of the sEH binding site. Furthermore, the ethyl linker was slightly preferred. Unfortunately, none of the compounds was able to activate any of the PPAR subtypes at a concentration of 30 μM, which forced us to pursue a different scaffold.

We decided to exchange the urea by an amide residue as epoxide mimetic for sEH targeting and chose the N-benzyl amide of isonicotinic acid moiety present in the clinical candidate GSK2256294A that targets sEH.17 N-Benzylamides are also known as privileged structures in the design of PPAR agonists with different subtype preferences, represented by KCL.18,19 The synthesis of the chimera compounds 5a–d was accomplished by isobutyl chloroformate (IBCF) mediated amide coupling of 2-trifluoromethylbenzylamine and 1-(4-formylphenyl)piperidine-4-carboxylic acid. The resulting ethyl cinnamate derivatives 5a and 5d were obtained under Wittig–Horner conditions followed by reduction with magnesium in methanol and saponification under microwave conditions as described before (Scheme 2).

All derivatives 5a–d exhibited sEH nanomolar inhibition. Since acids and the corresponding esters showed less differences in activity, we assumed that the scaffold was very well-tolerated by sEH. However, again no activity on PPARs could be determined. Encouraged by the robust sEH inhibitory activity of N-benzyl amides we fused this element with the 4-chloro-2-thio-pyrimidine scaffold which has been described in various studies as a privileged structure for PPAR activation.20 The synthesis of compounds 8c and 8d is shown in Scheme 3. 2-((4,6-Dichloropyrimidine-2-yl)thio)octanoate was prepared as described previously.21 Boc-protected γ-amino acids were coupled to 2-trifluoromethylbenzylamine mediated by IBCF, followed by Boc cleavage. Scaffold fusion was accomplished under basic conditions in acetonitrile, followed by saponification.

Compounds 8a–d showed sEH inhibitory potency in a low micromolar to submicromolar range. As observed for other scaffolds, acidic derivatives suffered a 4–6-fold loss in potency. Rigidified derivatives 8a and 8e were not active on PPARs, while compound 8d partially activated PPARα and PPARγ and finally represented the desired triple active agent. In order to examine PPAR activation under native conditions, mouse fibroblasts were incubated with 8d and a dose-dependent adipocyte differentiation could be observed (Fig. 2). Notably the absolute extend of adipocyte differentiation was significantly lower compared to the full agonist...
rosiglitazone, confirming the favourable partial PPAR agonistic properties of 8d.

An established pharmacophore of dual PPAR agonists consists of an acidic head group, a central aromatic ring, and an additional lipophilic substituent connected to the aromatic ring by a flexible linker. It is well-established that PPAR ligands should be able to adopt a conformation wrapped around helix 3. We investigated the differences between 8c and 8d considering the conformational space. While the flexible linker of 8d allows such conformation, it is almost impossible for the rigid derivative 8c (Fig. 3). With its combined potency on sEH and PPARs, 8d represents a very promising lead in the search for novel compounds to treat MetS and further studies are warranted (Table 1).

**Experimental**

**General**

All starting materials, reagents and solvents were purchased from Alfa-Aesar (Karlsruhe, Germany), Sigma-Aldrich (Hanover, Germany), Sigma-Aldrich Ltd (Manchester, England), JRD Fluorochemicals, Ltd. (Surrey, England), Axon Medchem BV (Groningen, Netherlands) and used without further purification. TLC was performed using silica coated aluminum foil (particle size 60 μm) purchased from Merck KGaA (Darmstadt, Germany). Purification of synthesized compounds was performed on an Inteli Flash 310 Chromatograph from Varian Medical Systems (Darmstadt, Germany) using SF25-60 g and SF25-60 g columns, both loaded with silica gel (particle size 50 μm) and also purchased from Varian Medical Systems (Darmstadt, Germany). 1H (250/400 MHz) and 13C (64 MHz) were recorded on DPX250 and AV400 nuclear magnetic resonance spectrometers from Bruker (Karlsruhe, Germany). All spectra were analyzed with TopSpin software (Bruker, Karlsruhe, Germany). Tetramethylsilane was used as internal standard.

General procedure for preparation of compounds 1a–b, using the example of ethyl 2-(4-cyanophenoxy)propanoate (1a).

**Ethyl 2-(4-(cyanomethyl)phenoxy)propanoate (1b).** Remained as a white powder (2 g, 38%); 1H NMR (250 MHz, DMSO-d6): δ = 7.75 (d, J = 8.9 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 5.13 (q, J = 7.2 Hz, 1H), 4.13 (q, J = 8.01 Hz, 2H), 1.52 (d, J = 6.9 Hz, 3H), 1.15 ppm (t, J = 7.3 Hz, 3H); MS-ESI+: m/z 242 [M + Na]+.

**General procedure for preparation of compounds 2a–b, using the example of ethyl 2-(4-aminomethyl)phenoxy)propanoate (2a).** 1.0 g (4.6 mmol) ethyl 2-(4-cyanophenoxy)propanoate (1a), 0.1 g (0.21 mmol) palladium on carbon 10% and 0.78 ml (13.68 mmol) glacial acetic acid were stirred in 10 ml dry ethanol under argon atmosphere for 24 h. The catalyst was segregated over Celite® and the solvent was removed under reduced pressure. The crude residue was dissolved in 30 ml ethyl acetate, washed three times with 2 M sodium hydroxide solution and twice with 30 ml brine. The organic layer was dried over magnesium sulfate and the solvent was removed under reduced pressure. The crude residue was dissolved in 30 ml of 2 M hydrochloric acid and washed with 20 ml cyclohexane. To the aqueous solution was added 1 M potassium hydroxide solution the pH...
was adjusted to a basic level. The aqueous layer was extracted with 25 ml ethyl acetate. The organic layer was dried over magnesium sulfate and the solvent was removed under reduced pressure. Without further purification, 2a remained as clear oil (0.69 g, 68%); 1H NMR (250 MHz, DMSO-d6): δ = 7.21–6.6 (m, 4H), 4.77 (q, J = 6.8 Hz, 1H), 4.12 (q, J = 6.7 Hz, 2H), 2.65 (s, 2H), 1.5 (d, J = 6.8 Hz, 3H), 1.18 ppm (t, J = 6.9 Hz, 3H); MS-ESI+: m/z 246 [M + Na]+.

Ethyl 2-(4-(aminomethyl)phenoxy)propanoate (2b). Remaining as clear oil (0.67 g, 66%); 1H NMR (250 MHz, DMSO-d6): δ = 7.13–6.75 (m, 4H), 4.87 (q, J = 6.9 Hz, 1H), 4.14 (q, J = 7 Hz, 2H), 2.7 (t, J = 6.1, 2H), 2.6 (t, J = 6.5, 2H), 1.49 (d, J = 6.8 Hz, 3H), 1.18 ppm (t, J = 6.8 Hz); MS-ESI+: m/z 260 [M + Na]+.

General procedure for preparation of compounds 3a–b, using the example of ethyl 2-(4-((3-(4-chlorophenyl)ureido)methyl)phenoxy)propanoate (3a). 0.5 g (2.24 mmol) ethyl 2-(4-(aminomethyl)phenoxy)propanoate (2a), 0.59 ml (3.36 mmol) N,N-dioisopropylethylamine and 0.29 ml (2.24 mmol) 4-chlorophenyl isocyanate were stirred in 5 ml dry dichloromethane under argon for 24 h. Then, the reaction mixture was diluted with further 10 ml dichloromethane and washed with 1 M hydrochloric acid. The organic layer was dried over magnesium sulfate and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography with hexane/ethyl acetate 3:1. Compound 3a remained as a white powder (0.17 g, 20%); 1H NMR (250 MHz, DMSO-d6): δ = 8.7 (s, 1H), 7.5–6.6 (m, 8H), 5.78 (t, J = 6.3 Hz, 1H), 4.92 (q, J = 6.7 Hz, 1H), 4.22 (d, J = 5.7 Hz, 2H), 4.14 (q, J = 6.8 Hz, 2H), 1.5 (d, J = 6.7 Hz, 3H), 1.18 ppm (t, J = 7.6 Hz, 3H); 13C NMR (75.4 MHz, DMSO-d6): 172, 159.1, 154.1, 134.9, 132.3, 129.4, 129.3, 129.1, 128.6, 124.2, 119.1, 114.3, 114.6, 79, 61.3, 50.9, 17.2, 12.3 ppm; HRMS-MALDI m/z [M + H]+ calcd for C19H21ClN2O4: 376.1193, found 376.1192.

Ethyl 2-(4-((3-(4-chlorophenyl)ureido)ethyl)phenoxy)propanoate (3b). Remaining as a white powder (0.15 g, 18%); 1H NMR (250 MHz, DMSO-d6): δ = 8.62 (s, 1H), 7.44–6.8 (m, 8H), 6.13 (t, J = 5.3 Hz, 1H), 4.9 (q, J = 6.7 Hz, 1H), 4.15 (q, J = 8 Hz, 2H), 2.68 (t, J = 8.1 Hz, 2H), 1.5 (d, J = 6.1 Hz, 3H), 1.18 ppm (t, J = 6.6 Hz, 3H); 13C NMR (75.4 MHz, DMSO-d6): 173, 162.1, 149.1, 136.9, 134.3, 130.4, 129.7, 129.2, 128.9, 128.6, 120, 119.5, 114.9, 114, 80, 61.4, 48.5, 36.7, 18.2, 11.3 ppm; HRMS-MALDI m/z [M + H]+ calcd for C20H23ClN2O4: 390.1351, found 390.1352.

General procedure for synthesis of compounds 3c–d, 5c, 5d, using the example of 2-(4-((3-(4-chlorophenyl)ureido)methyl)phenoxy)propanoic acid (3c). 100 mg (0.27 mmol) ethyl 2-(4-((3-(4-chlorophenyl)ureido)methyl)phenoxy)propanoate (3a) and 74 mg (1.33 mmol) potassium hydroxide were dissolved in 2 ml of a solvent mixture containing tetrahydrofuran, water and methanol in a ratio 1/2/1 and stirred under microwave irradiation in a Initiator Microwave Synthesizer from Biotage (Uppsala, Sweden) at 70 °C for 30 minutes. The organic solvents were removed under reduced pressure. With the addition of a few drops 12 M hydrochloric acid 3c precipitated in the aqueous phase. After filtration the product was dried by lyophilization and 3c remained as white powder (42 mg, 45%); 1H NMR (250 MHz, DMSO-d6): δ = 8.9 (s, 1H), 7.45–6.8 (m, 8H), 6.58 (t, J = 5.75 Hz, 1H), 4.8 (q, J = 6.5 Hz, 1H), 4.21 (d, J = 6.1 Hz, 2H), 1.49 ppm (d, J = 7.2 Hz, 3H); 13C NMR (75.4 MHz, DMSO-d6): 178, 159.1, 147.1, 135.9, 133.3, 131.4, 129.9, 129.7, 128.7, 119, 118.1, 114.3, 113, 76, 49.5, 19.2 ppm, HRMS-MALDI m/z [M + H]+ calcd for C18H17ClN2O4: 348.0883, found 348.0883.

2-(4-((3-Chlorophenyl)ureido)ethyl)phenoxy)propionic acid (3d). Remaining as a white powder (39 mg, 42%); 1H NMR (250 MHz, DMSO-d6): δ = 8.63 (s, 1H), 7.44–6.79 (m, 8H), 6.14 (t, J = 6 Hz, 1H), 4.78 (q, J = 6.5 Hz, 1H), 3.2 (q, J = 6.9 Hz, 2H), 1.49 ppm (d, J = 6.5 Hz, 3H); 13C NMR (75.4 MHz, DMSO-d6): 180, 159.1, 148.1, 137.2, 135.3, 129.9, 129.6, 129.2, 128.9, 128.5, 118, 117.5, 114.8, 114.1, 79.1, 49.5, 36.5, 18.1 ppm; HRMS-MALDI m/z [M + H]+ calcd for C19H17ClN2O4: 362.1032, found 362.1031.

General procedure for amide synthesis of compounds 4, 6a and 6b, described with the synthesis of 1-(4-formylphenyl)-N-(2-(trifluoromethylen)benzyl)piperidine-4-carboxamide (4). 1 g (4.29 mmol) 1-(4-formylphenyl)piperidine-4-carbonic acid, 0.66 ml (4.72 mmol) triethylamine and 0.61 ml (4.72 mmol) isobutyl chlorofomitate were stirred in 40 ml dry chlorofom at 0 °C under argon atmosphere for 1 h. Subsequently 0.66 ml...
(4.29 mmol) 2-(trifluoromethyl)benzylamine were added and the mixture was further stirred at room temperature for 12 h. The reaction mixture was washed three times with 20 ml of 2 M hydrochloric acid, three times with 20 ml of 2 M sodium hydroxide solution and two times with 20 ml brine. The organic layer was dried over magnesium sulfate and the solvent was removed under reduced pressure. The product was recrystallized from ethyl acetate/hexane. Compound 4 remained as a white powder (0.9 g, 54%); 1H NMR (250 MHz, DMSO-d$_6$): $\delta$ = 8.98 (s, 1H), 8.56 (t, J = 6.4 Hz, 1H), 7.82-7.12 (m, 8H), 4.53 (d, J = 6.1 Hz, 2H), 3.93-2.9 (m, 4H), 2.5 (m, 1H), 1.88-1.74 ppm (m, 4H); MS-ESI: m/z 425 [M + Cl$^-$].

Preparation of (E)-2-(4-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-yl)benzylidene)-alpha-ethylcinnamate (5a). 200 mg (5.12 mmol) sodium hydroxide 63% and 9.1 ml (3.84 mmol) triethyl phosphonoacetate were stirred in 5 ml dry tetrahydrofuran at 0°C under argon atmosphere for 30 minutes. Then, 1 g (2.56 mmol) 1-(4-formyl-phenyl)N-2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (4) was dissolved in 10 ml dry tetrahydrofuran and added to the reaction mixture. After 2 h the reaction was stopped with the addition of 25 ml water. The mixture was diluted with 10 ml ethyl acetate and washed three times with brine. The organic layer was dried over magnesium sulfate and the solvent was removed under reduced pressure. The product was recrystallized from ethyl acetate/hexane. Compound 5a remained as a white powder (901 mg, 68%); 1H NMR (250 MHz, DMSO-d$_6$): $\delta$ = 8.5 (t, J = 6.1 Hz, 1H), 7.75-7.05 (m, 9H), 4.47 (d, J = 7.4 Hz, 2H), 4.2 (q, J = 6.3 Hz, 2H), 3.92-2.8 (m, 4H), 2.9 (q, J = 12 Hz, 2H), 2.5 (m, 1H), 1.92-1.68 (m, 4H), 129 (t, J = 7.3 Hz, 3H), 1.14 ppm (t, J = 3.8 Hz, 3H); 13C NMR (75.4 MHz, DMSO-d$_6$); 179.6, 165, 142.9, 139.5, 135, 132.1, 132, 128, 129.1, 127.9, 127.8, 126.5, 125.2, 124.5, 113, 113.2, 112, 60, 51.6, 51, 39.3, 25.9, 25.8, 19.6, 13.9, 11.1; HRMS-MALDI m/z [M + H]$^+$ calculated for C$_{27}$H$_{27}$F$_3$N$_2$O$_3$: 490.2442, found 490.2441.

Preparation of tert-Butyl 4-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate (6a). 6a remained as an unclear oil (1.146 g, 68%); 1H NMR (250 MHz, DMSO-d$_6$): $\delta$ = 8.49 (t, J = 5.4 Hz, 1H), 7.78-7.49 (m, 4H), 4.49 (d, J = 5.4 Hz, 2H), 4.06-3.96 (m, 2H), 2.88-2.72 (m, 2H), 2.51-1.44 (m, 1H), 1.83-1.73 (m, 2H), 1.51-1.5 (m, 5H), 1.45 ppm (s, 9H). MS-ESI: m/z 410 [M + Cl$^-$].

tert-Butyl 4-((2-(trifluoromethyl)benzyl)aminobutyl)carbamate (6b). 6b remained as an unclear oil (0.975 g, 55%); 1H NMR (250 MHz, DMSO-d$_6$): $\delta$ = 8.45 (t, J = 5.9 Hz, 1H), 7.79-7.5 (m, 4H), 6.88 (t, J = 9.1 Hz, 1H), 4.49 (d, J = 6 Hz, 2H), 2.98 (q, J = 6.6 Hz, 2H), 2.24 (t, J = 7.2 Hz, 2H), 1.7 (q, J = 7.3 Hz, 2H), 1.44 ppm (s, 9H). MS-ESI: m/z 383 [M + Na$^+$].

General procedure of Boc-protecting group cleavage for compounds 7a and 7b, described with the synthesis of N-2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (7a). 230 mg (0.6 mmol) tert-butyl 4-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate (6a) and 0.92 ml (11.9 mmol) trifluoroacetic acid were stirred in 4 ml dichloromethane for 60 minutes. The organic solvent was removed under reduced pressure and the crude residue was dissolved in 10 ml ethyl acetate. The addition of 8 M sodium hydroxide solution the pH was adjusted to a basic level and the product was extracted with ethyl acetate (3 × 15 ml). The organic layer was dried over magnesium sulfate and the solvent was removed under reduced pressure. Without further purification, 7a remained as a colorless oil (0.13 g, 76%); 1H NMR (250 MHz, DMSO-d$_6$): $\delta$ = 8.42 (t, J = 5.6 Hz, 1H), 7.79-7.48 (m, 4H), 4.48 (d, J = 6.2 Hz, 2H), 3.08-2.99 (m, 2H), 2.61-2.5 (m, 2H), 2.44-2.33 (m, 1H), 1.78-1.68 ppm (m, 2H), 1.46-1.6 (m, 2H). MS-ESI: m/z 287 [M + H$^+$].

4-Amino-N-2-(trifluoromethyl)benzyl)butanamide (7b). 7b remained as a colorless oil (71 mg, 50%); 1H NMR (250 MHz, DMSO-d$_6$): $\delta$ = 8.4 (t, J = 5.4 Hz, 1H), 7.74-7.45 (m, 4H), 4.44 (d, J = 5.6 Hz, 2H), 2.66 (t, J = 7.4 Hz, 2H), 2.23 (t, J = 7.1 Hz, 2H), 1.62 ppm (q, J = 7.1 Hz, 2H). MS-ESI: m/z 261 [M + H$^+$].

General procedure of compounds 8a and 8b is described by the synthesis of ethyl 2-((4-chloro-6-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-yl)pyrimidine-2-yl(thio)octanoate (8a). 100 mg ethyl 2-((4,6-dichloropyrimidine-2-yl)thio)octanoate...
were dissolved in 2 mL dry acetonitrile under argon atmosphere. A mixture of 0.04 mL (0.285 mmol) triethylamine and 81 mg (0.285 mmol) N-(2-trifluoromethyl)benzyl)piperidine-4-carboxamide (7a) was added slowly and the mixture was stirred for 12 h. With the addition of water, the product precipitated, was filtered off and dried by lyophilization. Without further purification, 8a remained as a white powder (0.116 g, 68%); 1H NMR (230 MHz, methanol-d₄): δ = 7.62–7.31 (m, 4H), 6.44 (s, 1H), 4.47 (s, 2H), 4.22 (t, J = 7.2 Hz, 1H), 4.07 (q, J = 7.3 Hz, 2H), 2.99–2.87 (m, 2H), 2.62–2.47 (m, 1H), 1.9–1.48 (m, 6H), 1.47–1.27 (m, 13H), 0.8 ppm (t, J = 7.6 Hz, 3H); 13C NMR (75.4 MHz, methanol-d₄): 178.8, 174.6, 171.2, 167.2, 160.6, 139.3, 131.7, 129.2, 127.4, 126.7, 125.1, 113.1, 102.8, 60.1, 52, 51.2, 44.7, 39.1, 35.2, 30.1, 29.8, 27.5, 25.7, 25.8, 32.6, 23.1, 14, 13.6; HRMS-MALDI m/z [M + H]+ calefd for C₂₇H₃₅ClF₃N₂O₃: 600.2154, found 600.2153.

Ethyl 2-(4-chloro-6-(4-((2-(trifluoromethyl)benzyl)carbamoyl)phenyl)piperidin-1-yl)pyrimidin-2-yl)octanoate (8b). 8b remained as a white powder (0.058 g, 50%); 1H NMR (250 MHz, methanol-d₄): δ = 7.62–7.3 (m, 4H), 6.07 (s, 1H), 4.47 (s, 2H), 4.29 (t, J = 7.3 Hz, 1H), 4.04 (q, J = 7.1 Hz, 2H), 3.49–3.27 (m, 2H), 2.27 (t, J = 7.2 Hz, 2H), 1.82 (q, J = 7.8 Hz, 2H), 1.38–1.11 (m, 13H), 0.79 (t, J = 7.1 Hz, 3H) ppm; 13C NMR (75.4 MHz, methanol-d₄): 178.9, 175.6, 170.2, 166.2, 158.6, 137.3, 134.7, 129.2, 128.4, 128.7, 126.1, 114.1, 103.8, 58.1, 50.6, 43.7, 34.2, 32.6, 31.7, 29.1, 28.8, 27.5, 27.4, 23.1, 14.7, 12.6; HRMS-MALDI m/z [M + H]+ calefd for C₂₅H₃₁ClF₃N₂O₃: 572.1850, found 572.1849.

PPAR activity assay

Evaluation of PPAR activity was performed as published before.24 In brief, COS-7 cells were grown in DMEM high glucose, supplemented with 10% fetal calf serum (FCS), 1% sodium pyruvate (SP) and 1% penicillin/streptomycin (PS) at 37 °C and 5% CO₂. The day before transfection, COS-7 cells were seeded in 96-well plates with a density of 30,000 cells per well. Transient transfection was carried out using Lipofectamine LTX reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol with pFR-Luc (Stratagene), pRL-SV40 (Promega) and the Gal4-fusion receptor plasmids (pFA-CMV-hPPAR-LBD) of the respective PPAR subtype. 5 h after transfection, medium was changed to DMEM without phenol red and 10% FCS, supplemented with 1% SP, 1% PS and 1% l-glutamine, now additionally containing 0.1% DMSO and the respective test compound or 0.1% DMSO alone as untreated control. Each concentration was tested in triplicate wells and each experiment was repeated independently at least three times. Following overnight incubation with the test compounds, cells were assayed for luciferase activity using Dual-Glo™ Luciferase Assay System (Promega) according to the manufacturer’s protocol. Luminescence was measured using a microplate reader (Infinite M200, Tecan Group Ltd., Crailsheim, Germany). Normalization for transfection efficacy and cell growth was done by division of the Firefly luciferase data by Renilla luciferase data resulting in relative light units. Activation factors were obtained by dividing by DMSO control. EC₅₀ and standard deviation values were calculated by mean values of at least three determinations by SigmaPlot 2001 (Systat Software GmbH, Erkrath, Germany) using a four-parameter logistic regression. All compounds were evaluated by comparison of the achieved maximum effect to that of the reference compound (pioglitazone for PPARγ, GW7647 for PPARα,25 and L165041 for PPARδ26 each at 1 μM). Data are expressed as mean ± SE; n ≥ 3.

SEH activity assay

The IC₅₀ values of the compounds were determined by a fluorescence-based assay system of 96-well format. As substrate non-fluorescent PHOME (3-phenyl-cyano-(6-methoxy-2-naphthalenyl)methyl ester-2-oxirane-acetic acid, Cayman Chemicals) was used, which can be hydrolyzed by the sEH to the fluorescent 6-methoxynaphthaldehyde.27 The formation of the product was measured (λex = 330 nm, λem = 465 nm) by a Tecan Infinite F200 Pro plate reader. Therefore, recombiant human sEH (2 μg per well) in Bis-Tris buffer pH 7 with 0.1 mg mL⁻¹ BSA containing a final concentration of 0.01% Triton-X 100. 100 μL of protein were incubated with different concentrations of compounds (DMSO) with final concentration of 1% for 30 min. at room temperature. After that 10 μL of substrate were added (final concentration 50 μM). The hydrolysed substrate was measured for 30 min (one point every minute). A blank control (no protein and no compound) as well as a positive control (no compound) was executed. All measurements were performed in triplicates.
Differentiation of murine 3T3-L1 cells

3T3-L1 cells were subcultured in DMEM containing 10% newborn calf serum in a humidified atmosphere at 37 °C, 5% CO₂. Cells were differentiated into adipocytes for 14 days according to the method of Zebisch et al. Briefly, cells were seeded in 6-well plates (2.5 × 10⁵ per well). Differentiation was started at day 3 by addition of 1 μg ml⁻¹ insulin, 0.25 μM dexamethasone and 0.5 mM isobutylmethylxanthine in DMEM supplemented with 10% fetal calf serum. At day 5 medium was replaced by medium containing only insulin for 2 more days. After this, cells were kept for lipid droplet accumulation in basal medium without additions until day 15. Rosiglitazone (2 μM) and 0.5 mM isobutylmethylxanthine in DMEM supplemented to the general pharmacophore of PPAR agonists, only and PPAR positive controls, respectively. Differentiation of 3T3-L1 cells was confirmed by Oil Red O staining. Cells were washed with PBS and subsequently fixed for 60 minutes with a formaldehyde solution (4% in PBS). After this, cells were rinsed with 60% isopropanol and incubated with Oil Red O solution (0.3%) for 120 minutes.

Conclusions

In this study diverse scaffolds of sEH inhibitors and PPAR agonists were fused in order to obtain a dual sEH/PPAR modulator. All three designed compound classes displayed potent inhibitory activity against sEH. Obviously, inhibitory activity against sEH can be easily introduced in a multi-target compound by incorporating a secondary urea or N-benzyl benzamide fragment, as it was previously shown by Hwang et al. and Meier et al. However, this does not hold true for PPAR activation. Although all compounds corresponded to the general pharmacophore of PPAR agonists, only 8d displayed the desired PPAR modulatory activity. Even small changes in the linker region of bezafibrate displayed in 3c and 3d led to complete loss of PPAR agonistic properties. This observation is in line with our previous observation on dual sEH/PPAR modulators, where almost all members of a combinatorial library displayed sEH inhibitory activity, whereas only few compounds were indeed able to activate PPARγ and PPARα. Small N-benzyl benzamides were previously identified as a merged pharmacophores of dual sEH/PPARγ modulators with oral activity, however without impact on PPARα. Thus, it seems to be difficult to design-in sEH inhibitory activity in a dual PPARα/γ agonist.

The triple active agent 8d resulting from this study is an interesting tool for the investigation of multi-target compounds for MetS treatment. Due to the fact that it comprises sEH inhibitory and PPARα/γ partial agonistic properties, it might simultaneously reduce dyslipidaemia, hyperglycaemia, and hypertension. With its partial agonistic profile on both PPAR subtypes, 8d should also be less prone of the typical TZD side effects including weight-gain and edema causing fluid retention. Further in vivo evaluation of 8d will provide valuable insights into multi-target treatment options for MetS.

Acknowledgements

This work was supported by the Else-Kröner-Fresenius Foundation graduate school Translational Research Innovation Pharma (TRIP) and Deutsche Forschungsgemeinschaft (DFG; Sachbeihilfe PR1405/1-2; SFB 1039 Teilprojekt A07). R. B. and O. D. thank the graduate school Translational Research Innovation Pharma (TRIP) for PhD scholarships.

Notes and references

1. E. S. Ford, W. H. Giles and W. H. Dietz, *JAMA*, 2002, 287, 356–359.
2. R. H. Eckel, S. M. Grundy and P. Z. Zimet, *Lancet*, 2005, 365, 1415–1428.
3. S. M. Grundy, *Nat. Rev. Drug Discovery*, 2006, 5, 295–309.
4. D. V. Rollason and N. Vogt, *Drugs Aging*, 2012, 20, 817–832.
5. M. G. Katselou, A. N. Matralis and A. P. Kourounakis, *Curr. Med. Chem.*, 2014, 21, 2743–2787.
6. J. D. Imig, K. A. Walsh, M. A. Hye Khan, T. Nagasawa, M. Cherian-Shaw, S. M. Shaw and B. D. Hammock, *Exp. Biol. Med.*, 2012, 237, 1402–1412.
7. C. Duval, M. Müller and S. Kersten, *Biochim. Biophys. Acta, Mol. Cell Biol. Lipids*, 2007, 1771, 961–971.
8. C. Lamers, M. Schubert-Zsilavecz and D. Merk, *Expert Opin. Ther. Pat.*, 2012, 22, 803–841.
9. I. Fleming, *Pharmacol. Rev.*, 2014, 66, 1106–1140.
10. J. Wray and D. Bishop-Bailey, *Exp. Physiol.*, 2008, 93, 148–154.
11. B. M. De Taeye, C. Morisseau, J. Coyle, J. W. Covington, A. Luria, J. Yang, S. B. Murphy, D. B. Friedman, B. B. Hammock and D. E. Vaughan, *Obesity*, 2010, 18, 489–498.
12. Y. Liu, Y. Zhang, K. Schmelzer, T.-S. Lee, X. Fang, Y. Zhu, A. A. Spector, S. Gill, C. Morisseau, B. D. Hammock and J. -J. Shy, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, 102, 16747–16752.
13. D. Xu, B. B. Davis, Z. Wang, S. Zhao, B. Wasti, Z. Liu, N. Li, C. Morisseau, N. Chiamvimonvat and B. D. Hammock, *Int. J. Cardiol.*, 2013, 167, 1298–1304.
14. E. Buscató, R. Böcher, C. Lamers, F.-M. Klingler, S. Hahn, D. Steinhalber, M. Schubert-Zsilavecz and E. Proschak, *J. Med. Chem.*, 2012, 55, 10771–10775.
15. G. A. Gomez, C. Morisseau, B. D. Hammock and D. W. Christianson, *Biochemistry (Moscow)*, 2004, 43, 4716–4723.
16. T. Asaki, T. Aoki, T. Hamamoto, Y. Sugiyama, S. Oohama, K. Kuwabara, K. Murakami and M. Todo, *Bioorg. Med. Chem.*, 2008, 16, 981–994.
17. P. L. Podolin, B. J. Bolognese, J. F. Foley, E. Long, B. Peck, S. Umbrecht, X. Zhang, P. Zhu, B. Schwartz, W. Xie, C. Quinn, H. Qi, S. Sweitzer, S. Chen, M. Galop, Y. Ding, S. L. Belyanskaya, D. I. Israel, B. A. Morgan, D. J. Behm, J. P. Marino, E. Kurali, M. S. Barnette, R. J. Mayer, C. L. Booth-Bentgen and J. F. Callahan, *Prostaglandins Other Lipid Mediators*, 2013, 104-105, 25–31.
18. M. Nomura, T. Tanase, T. Ide, M. Tsunoda, M. Suzuki, U. Uchiki, K. Murakami and H. Miyachi, *J. Med. Chem.*, 2003, 46, 3581–3599.
Research Article

19 M. Ohashi, I. Nakagome, J.-I. Kasuga, H. Nobusada, K. Matsuno, M. Makishima, S. Hirono, Y. Hashimoto and H. Miyachi, *Bioorg. Med. Chem.*, 2012, 20, 6375–6383.

20 D. Merk, M. Zettl, D. Steinhilber, O. Werz and M. Schubert-Zsilavecz, *Future Med. Chem.*, 2015, 7, 1597–1616.

21 C. Lamers, M. Dittrich, R. Steri, E. Proschak and M. Schubert-Zsilavecz, *Bioorg. Med. Chem. Lett.*, 2014, 24, 4048–4052.

22 G. Navarrete-Vázquez, H. Torres-Gómez, S. Hidalgo-Figueroa, J. J. Ramírez-Espinosa, S. Estrada-Soto, J. L. Medina-Franco, I. León-Rivera, F. J. Alarcón-Aguilar and J. C. Almanza-Pérez, *Bioorg. Med. Chem. Lett.*, 2014, 24, 4575–4579.

23 H. E. Xu, M. H. Lambert, V. G. Montana, K. D. Plunket, L. B. Moore, J. L. Collins, J. A. Oplinger, S. A. Kliwer, R. T. Gampe, D. D. McKee, J. T. Moore and T. M. Willson, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, 98, 13919–13924.

24 O. Rau, M. Wurglics, A. Paulke, J. Zitzkowski, N. Meindl, A. Bock, T. Dingermann, M. Abdel-Tawab and M. Schubert-Zsilavecz, *Planta Med.*, 2006, 72, 881–887.

25 P. J. Brown, L. W. Stuart, K. P. Hurley, M. C. Lewis, D. A. Winegar, J. G. Wilson, W. O. Wilkison, O. R. Ittoop and T. M. Willson, *Bioorg. Med. Chem. Lett.*, 2001, 11, 1225–1227.

26 J. Berger, M. D. Leibowitz, T. W. Doebber, A. Elbrecht, B. Zhang, G. Zhou, C. Biswas, C. A. Cullinan, N. S. Hayes, Y. Li, M. Tanen, J. Venture, M. S. Wu, G. D. Berger, R. Mosley, R. Marquis, C. Santini, S. P. Sahoo, R. L. Tolman, R. G. Smith and D. E. Moller, *J. Biol. Chem.*, 1999, 274, 6718–6725.

27 N. M. Wolf, C. Morisseau, P. D. Jones, B. Hock and B. D. Hammock, *Anal. Biochem.*, 2006, 355, 71–80.

28 K. Zebisch, V. Voigt, M. Wabitsch and M. Brandsch, *Anal. Biochem.*, 2012, 425, 88–90.

29 S. H. Hwang, K. M. Wagner, C. Morisseau, J.-Y. Liu, H. Dong, A. T. Wecksler and B. D. Hammock, *J. Med. Chem.*, 2011, 54, 3037–3050.

30 K. Meirer, C. B. Rödl, J. M. Wisniewska, S. George, A.-K. Häfner, E. Buscatò, F.-M. Klingler, S. Hahn, D. Berressem, S. K. Wittmann, D. Steinhilber, B. Hofmann and E. Proschak, *J. Med. Chem.*, 2013, 56, 1777–1781.

31 H. Zettl, R. Steri, M. Lämmerhofer and M. Schubert-Zsilavecz, *Bioorg. Med. Chem. Lett.*, 2009, 19, 4421–4426.

32 R. Blöcher, C. Lamers, S. K. Wittmann, D. Merk, M. Hartmann, L. Weizel, O. Diehl, A. Brüggerhoff, M. Boß, A. Kaiser, T. Schader, T. Göbel, M. Grundmann, C. Angioni, J. Heering, G. Geisslinger, M. Wurglics, E. Kostenis, B. Brüne, D. Steinhilber, M. Schubert-Zsilavecz, A. S. Kahnt and E. Proschak, *J. Med. Chem.*, 2016, 59, 61–81.